Align Technology (XTER:AFW) Research & Development: €319 Mil (TTM As of Mar. 2026)


XTER:AFW Align Technology Inc XTER:AFW
89 GF Score
Price €149.05
GF Value €212.06
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Align Technology Research & Development?

Align Technology XTER:AFW 89 Research & Development is €319 Mil as of Mar. 2026. GuruFocus rates XTER:AFW with a GF Score™ of 89/100 and a GF Value™ of €212.06 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Align Technology's Research & Development for the three months ended in Mar. 2026 was €85 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €319 Mil.

Align Technology  (XTER:AFW) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Align Technology Research & Development Related Terms

Align Technology Research & Development Historical Data

* Premium members only.

The historical data trend for Align Technology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Align Technology Research & Development Chart

Align Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 221.53 288.16 318.04 347.81 315.90

Align Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.91 83.58 79.47 70.91 85.34
XTER:AFW
89GF Score
Align Technology Inc XTER:AFW
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Align Technology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €319 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €319 Mil mean?
Align Technology (XTER:AFW) has a Research & Development of €319 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Align Technology and its competitors.
Is Align Technology's Research & Development too high?
Align Technology's current Research & Development is €319 Mil. Overall, Align Technology has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Align Technology's Research & Development compare to SOLV and COO?
Align Technology's Research & Development of €319 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Align Technology and its competitors. Align Technology's current Research & Development is €319 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Align Technology stock overvalued right now?
Based on GuruFocus' analysis, Align Technology (XTER:AFW) is currently considered Significantly Undervalued. The stock's GF Value™ is €212.06, compared to a current price of €149.05 — trading 29.7% below its estimated fair value. The current Research & Development is €319 Mil. Align Technology's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Align Technology (XTER:AFW), the current Research & Development is €319 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Align Technology (XTER:AFW) Overvalued in 2026?

Based on GuruFocus' analysis, Align Technology stock appears to be undervalued. The current stock price of €149.05 is trading 29.7% below its estimated GF Value™ of €212.06. GuruFocus considers Align Technology to be Significantly Undervalued.

Key valuation signals for XTER:AFW:

  • Research & Development: €319 Mil
  • GF Value™: €212.06 vs. price of €149.05 (29.7% below fair value)
  • GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the XTER:AFW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Align Technology Business Description

Address 410 North Scottsdale Road, Suite 1300, Tempe, AZ, USA, 85288
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
89GF Score

Get the complete analysis for XTER:AFW

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€149.05
Price
€212.06
GF Value